Hovione Technology acquires global rights to new pulmonary inhaler device

15 Apr 2019

The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.

Hovione Technology has secured global rights to develop and commercialize a new ultra-affordable, multi-use blister-based dry powder inhaler (DPI) patented by inventor Dr Klaus-Dieter Beller. The two parties will continue to collaborate on the inhaler, which will be marketed as the Papillon DPI.

Hovione Technology acquires global rights to new pulmonary inhaler device
Papillon - multi-use blister DPI.

The Papillon DPI is a single-part, blister-based, reusable inhaler of extreme simplicity, suitable for both chronic and acute treatments. It can accommodate a single or double blister configuration, enabling ultra-affordable drug therapies at global scale.

Papillon unlocks a paradigm shift for pharmaceutical companies developing new inhaled drugs: unit dose costs competitive to multi-dose inhalers at a fraction of the development cost and risk associated with complex devices.

Hovione Technology’s CEO Peter Villax said: “This is a strategic DPI development for Hovione Technology which emphasizes our long-term commitment to offer market access to a portfolio of innovative inhalers that maximize simplicity of use, drug delivery performance and cost-effectiveness on a truly global scale. We are delighted to accelerate commercialization of this innovative blister DPI”.

Hovione Technology has a co-promotional agreement with API manufacturer Hovione and together they are able to provide access to a complete portfolio of innovative DPI devices integrated with inhalation API, formulation development and industrial manufacturing to pharmaceutical companies focusing on inhaled drugs.

Read More

Related news

Clinical supply milestone reached for triple-negative breast cancer treatment

Clinical supply milestone reached for triple-negative breast cancer treatment

12 Jun 2019

PhoenixMD and WuXi STA have produced a multikilogram drug supply for PMD-026 under GMP manufacturing practices.

Read more 
Trial finds vitamin D does not prevent type 2 diabetes in people at high risk

Trial finds vitamin D does not prevent type 2 diabetes in people at high risk

11 Jun 2019

No meaningful difference between the two study groups regardless of age, sex, race or ethnicity.

Read more 
Partnership seeks breath biomarkers for the early detection of malignant mesothelioma

Partnership seeks breath biomarkers for the early detection of malignant mesothelioma

6 Jun 2019

Owlstone Medical and IAHFIAW to use Breath Biopsy to examine the chemicals found on the breath of individuals with documented historical exposure to asbestos and radiologically and histologically confirmed mesothelioma.

Read more 
Lilly gets its hands on non-opioid pain asset

Lilly gets its hands on non-opioid pain asset

4 Jun 2019

Early-phase molecule from Centrexion to be developed further as a potential non-opioid treatment option for multiple pain conditions.

Read more 
Updated clinical trial simulation software saves time and money

Updated clinical trial simulation software saves time and money

3 Jun 2019

One customer saves $25m and 3 years' development time in their clinical development strategy.

Read more 
Merck bolsters oncology pipeline with acquisition

Merck bolsters oncology pipeline with acquisition

22 May 2019

Acquisition includes novel late-stage renal cell carcinoma candidate, PT2977.

Read more 
Follicum files patent application for new topical formulation for hair loss

Follicum files patent application for new topical formulation for hair loss

30 Apr 2019

Using easy-to-apply cream instead of direct scalp injection would extend patent protection by 8 years.

Read more 
Isotype-specific secondary antibodies for improved signal detection

Isotype-specific secondary antibodies for improved signal detection

10 Apr 2019

Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.

Read more 
Sterling Pharma to acquire CiVentiChem in the US

Sterling Pharma to acquire CiVentiChem in the US

9 Apr 2019

The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.

Read more 
Catalent expands OptiMelt hot melt extrusion capabilities

Catalent expands OptiMelt hot melt extrusion capabilities

4 Apr 2019

The investment includes the addition of equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.

Read more